Arimidex in McCune Albright Syndrome

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

See also
Status	Clinical Trial	Phase
Completed	`NCT00278915` - Faslodex in McCune-Albright Syndrome	Phase 2
Recruiting	`NCT00001727` - Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome
Withdrawn	`NCT03520153` - Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome
Completed	`NCT00318097` - Histamine Responsiveness in McCune-Albright Syndrome	N/A

See also

Status

Clinical Trial

Phase

Completed

NCT00278915 - Faslodex in McCune-Albright Syndrome

Phase 2

Recruiting

NCT00001727 - Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome

Withdrawn

NCT03520153 - Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome

Completed

NCT00318097 - Histamine Responsiveness in McCune-Albright Syndrome

N/A

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT00055302
Study type	Interventional
Source	AstraZeneca
Contact
Status	Completed
Phase	Phase 2
Start date	August 2002
Completion date	August 2015

Arimidex in McCune Albright Syndrome

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms